
Andrea Balsari

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3951733/publications.pdf Version: 2024-02-01



ANDDEA RAISADI

#	Article	IF	CITATIONS
1	Regulation of the macrophage content of neoplasms by chemoattractants. Science, 1983, 220, 210-212.	12.6	336
2	FOXP3 Expression and Overall Survival in Breast Cancer. Journal of Clinical Oncology, 2009, 27, 1746-1752.	1.6	271
3	Toll-like Receptors 3, 4, and 7 Are Expressed in the Enteric Nervous System and Dorsal Root Ganglia. Journal of Histochemistry and Cytochemistry, 2009, 57, 1013-1023.	2.5	237
4	HER2 as a Prognostic Factor in Breast Cancer. Oncology, 2001, 61, 67-72.	1.9	216
5	Low Molecular Weight Hyaluronic Acid Increases the Self-Defense of Skin Epithelium by Induction of β-Defensin 2 via TLR2 and TLR4. Journal of Immunology, 2008, 181, 2103-2110.	0.8	155
6	Role of HER2 in wound-induced breast carcinoma proliferation. Lancet, The, 2003, 362, 527-533.	13.7	152
7	Antitumor Activity of the TLR-5 Ligand Flagellin in Mouse Models of Cancer. Journal of Immunology, 2006, 176, 6624-6630.	0.8	148
8	Degranulation of Paneth Cells via Toll-Like Receptor 9. American Journal of Pathology, 2004, 165, 373-381.	3.8	142
9	Modulation of Pulmonary Microbiota by Antibiotic or Probiotic Aerosol Therapy: A Strategy to Promote Immunosurveillance against Lung Metastases. Cell Reports, 2018, 24, 3528-3538.	6.4	141
10	Activation of Enteroendocrine Cells via TLRs Induces Hormone, Chemokine, and Defensin Secretion. Journal of Immunology, 2007, 178, 4296-4303.	0.8	117
11	Role of exon-16-deleted HER2 in breast carcinomas. Endocrine-Related Cancer, 2006, 13, 221-232.	3.1	112
12	The lung microbiota: role in maintaining pulmonary immune homeostasis and its implications in cancer development and therapy. Cellular and Molecular Life Sciences, 2020, 77, 2739-2749.	5.4	103
13	HER2 Overexpression and Doxorubicin in Adjuvant Chemotherapy for Resectable Breast Cancer. Journal of Clinical Oncology, 2003, 21, 458-462.	1.6	99
14	Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clinical Cancer Research, 1997, 3, 817-9.	7.0	97
15	Exploiting poly(I:C) to induce cancer cell apoptosis. Cancer Biology and Therapy, 2017, 18, 747-756.	3.4	92
16	Primary but not metastatic human melanomas expressing dr antigens stimulate autologous lymphocytes. International Journal of Cancer, 1984, 33, 591-597.	5.1	91
17	FOXP3 expression in tumor cells and implications for cancer progression. Journal of Cellular Physiology, 2013, 228, 30-35.	4.1	87
18	Nerve growth factor suppresses the transforming phenotype of human prolactinomas Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 7961-7965.	7.1	80

#	Article	IF	CITATIONS
19	HER2 as a target for breast cancer therapy. Expert Opinion on Biological Therapy, 2010, 10, 711-724.	3.1	78
20	Critical Role of TLR9 in Acute Graft-versus-Host Disease. Journal of Immunology, 2008, 181, 6132-6139.	0.8	70
21	miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response. Oncotarget, 2016, 7, 786-797.	1.8	70
22	The 67 kDa laminin receptor increases tumor aggressiveness by remodeling laminin-1. Endocrine-Related Cancer, 2005, 12, 393-406.	3.1	69
23	Therapeutic Synergism of Gemcitabine and CpG-Oligodeoxynucleotides in an Orthotopic Human Pancreatic Carcinoma Xenograft. Cancer Research, 2005, 65, 6388-6393.	0.9	68
24	CCN3/Nephroblastoma Overexpressed Matricellular Protein Regulates Integrin Expression, Adhesion, and Dissemination in Melanoma. Cancer Research, 2008, 68, 715-723.	0.9	64
25	The inhibition of lymphocyte stimulation by autologous human metastatic melanoma cells correlates with the expression of HLA-DR antigens on the tumor cells. International Journal of Cancer, 1984, 34, 797-806.	5.1	63
26	Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer. Cancer Research, 2021, 81, 2195-2206.	0.9	63
27	Activation of smooth muscle and myenteric plexus cells of jejunum via toll-like receptor 4. Journal of Cellular Physiology, 2006, 208, 47-54.	4.1	62
28	Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts. European Journal of Cancer, 2004, 40, 1275-1281.	2.8	59
29	HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clinical Cancer Research, 2002, 8, 520-5.	7.0	58
30	HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy. Oncolmmunology, 2019, 8, e1512942.	4.6	57
31	Induction of Paneth cell degranulation by orally administered Tollâ€like receptor ligands. Journal of Cellular Physiology, 2012, 227, 1107-1113.	4.1	56
32	Chemotactic activity for mononuclear phagocytes of culture supernatants from murine and human tumor cells: Evidence for a role in the regulation of the macrophage content of neoplastic tissues. International Journal of Cancer, 1983, 31, 55-63.	5.1	55
33	Expression of CD28 on CD8+ and CD4+ Lymphocytes During HIV Infection. Scandinavian Journal of Immunology, 1994, 40, 485-490.	2.7	54
34	Contribution of CD4+, CD8+CD28+, and CD8+CD28- T cells to CD3+ lymphocyte homeostasis during the natural course of HIV-1 infection Journal of Clinical Investigation, 1998, 101, 137-144.	8.2	52
35	Role of proliferation in HER2 status predicted response to doxorubicin. International Journal of Cancer, 2003, 105, 568-573.	5.1	49
36	Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors. Cellular Oncology, 2010, 32, 361-72.	1.9	48

#	Article	IF	CITATIONS
37	Oral administration of anti-doxorubicin monoclonal antibody prevents chemotherapy-induced gastrointestinal toxicity in mice. Cancer Research, 1996, 56, 2082-5.	0.9	48
38	Induction of pro-inflammatory programs in enteroendocrine cells by the Toll-like receptor agonists flagellin and bacterial LPS. International Immunology, 2008, 20, 961-970.	4.0	47
39	Nerve growth factor directs differentiation of the bipotential cell line GH-3 into the mammotroph phenotype Endocrinology, 1994, 135, 290-298.	2.8	44
40	Influence of Antibiotic Treatment on Breast Carcinoma Development in Proto-neu Transgenic Mice. Cancer Research, 2006, 66, 6219-6224.	0.9	43
41	CD11b Expression Identifies CD8+CD28+T Lymphocytes with Phenotype and Function of Both Naive/Memory and Effector Cells. Journal of Immunology, 2001, 166, 900-907.	0.8	42
42	Neoplastic and Stromal Cells Contribute to an Extracellular Matrix Gene Expression Profile Defining a Breast Cancer Subtype Likely to Progress. PLoS ONE, 2013, 8, e56761.	2.5	41
43	Tamoxifen chemoprevention of a hormone-independent tumor in the proto-neu transgenic mice model. Cancer Research, 2000, 60, 273-5.	0.9	41
44	Nerve growth factor controls proliferation and progression of human prolactinoma cell lines through an autocrine mechanism. Molecular Endocrinology, 1996, 10, 272-285.	3.7	40
45	Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition. Oncotarget, 2016, 7, 255-265.	1.8	39
46	ELISA for toxoplasma antibody detection: a comparison with other serodiagnostic tests Journal of Clinical Pathology, 1980, 33, 640-643.	2.0	37
47	TLR9 Agonists Oppositely Modulate DNA Repair Genes in Tumor versus Immune Cells and Enhance Chemotherapy Effects. Cancer Research, 2011, 71, 6382-6390.	0.9	37
48	PDGFRÎ ² and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells. Molecular Oncology, 2014, 8, 968-981.	4.6	37
49	Poly(I:C) and CpG-ODN combined aerosolization to treat lung metastases and counter the immunosuppressive microenvironment. Oncolmmunology, 2015, 4, e1040214.	4.6	37
50	TLR3 Expression Induces Apoptosis in Human Non-Small-Cell Lung Cancer. International Journal of Molecular Sciences, 2020, 21, 1440.	4.1	37
51	Natural human antibodies to gamma interferon interfere with the immunomodulating activity of the lymphokine Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 4447-4451.	7.1	36
52	The Detection and Biological Activity of Human Antibodies to IL-2 in Normal Donors. Scandinavian Journal of Immunology, 1993, 38, 472-476.	2.7	35
53	Doxorubicin-Induced Alopecia Is Associated with Sebaceous Gland Degeneration. Journal of Investigative Dermatology, 2006, 126, 711-720.	0.7	35
54	Absence of the CD1 Molecule Up-Regulates Antitumor Activity Induced by CpG Oligodeoxynucleotides in Mice. Journal of Immunology, 2002, 169, 151-158.	0.8	34

#	Article	IF	CITATIONS
55	Stimulation of TLRs by LMWâ€HA induces selfâ€defense mechanisms in vaginal epithelium. Immunology and Cell Biology, 2011, 89, 630-639.	2.3	34
56	Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration. Oncotarget, 2015, 6, 28173-28182.	1.8	34
57	Sodium-Dependent Glucose Transporter-1 as a Novel Immunological Player in the Intestinal Mucosa. Journal of Immunology, 2008, 181, 3126-3136.	0.8	33
58	Cross-talk between Toll-like receptors 5 and 9 on activation of human immune responses. Journal of Leukocyte Biology, 2007, 82, 509-518.	3.3	32
59	Lysis of autologous human melanoma cells by in vitro allosensitized peripheral blood lymphocytes. Cancer Immunology, Immunotherapy, 1982, 14, 99-104.	4.2	31
60	Activity and resistance of trastuzumab according to different clinical settings. Cancer Treatment Reviews, 2012, 38, 212-217.	7.7	31
61	Prevention of spontaneous mammary adenocarcinoma in HERâ€2/neu transgenic mice by foreign DNA. FASEB Journal, 2002, 16, 1749-1754.	0.5	30
62	Biology, prognosis and response to therapy of breast carcinomas according to HER2 score. Annals of Oncology, 2008, 19, 1706-1712.	1.2	30
63	Reprogramming the lung microenvironment by inhaled immunotherapy fosters immune destruction of tumor. Oncolmmunology, 2016, 5, e1234571.	4.6	30
64	Cross-talk among Toll-like receptors and their ligands. International Immunology, 2008, 20, 709-718.	4.0	28
65	Systemic administration of autologous, alloactivated helper-enriched lymphocytes to patients with metastatic melanoma of the lung. Cancer Immunology, Immunotherapy, 1986, 21, 148-55.	4.2	27
66	Dermatophytes in clinically healthy laboratory animals. Laboratory Animals, 1981, 15, 75-78.	1.0	26
67	CpGâ€oligodeoxynucleotides induce mobilization of hematopoietic progenitor cells into peripheral blood in association with mouse KC (ILâ€8) production. Journal of Cellular Physiology, 2005, 204, 889-895.	4.1	26
68	Ascites Regression and Survival Increase in Mice Bearing Advanced-stage Human Ovarian Carcinomas and Repeatedly Treated Intraperitoneally With CpG-ODN. Journal of Immunotherapy, 2010, 33, 8-15.	2.4	26
69	Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study. Breast Cancer Research and Treatment, 2013, 141, 101-110.	2.5	25
70	Activation of NK cell cytotoxicity by aerosolized CpG-ODN/poly(I:C) against lung melanoma metastases is mediated by alveolar macrophages. Cellular Immunology, 2017, 313, 52-58.	3.0	25
71	Detection of aberrant isotype switch recombination in low-grade and high-grade gastric MALT lymphomas. Blood, 2000, 95, 1032-1038.	1.4	25
72	Characterization of T Cell Subsets Involved in the Production of IFN-Î ³ in Asymptomatic HIV-Infected Patients. AIDS Research and Human Retroviruses, 1996, 12, 135-141.	1.1	24

#	Article	IF	CITATIONS
73	Fluctuation of HER2 Expression in Breast Carcinomas during the Menstrual Cycle. American Journal of Pathology, 1999, 155, 1543-1547.	3.8	24
74	EGFR through STAT3 modulates ΔN63α expression to sustain tumorâ€initiating cell proliferation in squamous cell carcinomas. Journal of Cellular Physiology, 2013, 228, 871-878.	4.1	24
75	Generation of CD28â^' cells from long-term-stimulated CD8+CD28+ T cells: a possible mechanism accounting for the increased number of CD8+CD28â^' T cells in HIV-1-infected patients. Journal of Leukocyte Biology, 1999, 65, 641-648.	3.3	23
76	Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts. European Journal of Cancer, 2005, 41, 1213-1222.	2.8	23
77	Eradication of Ovarian Tumor Xenografts by Locoregional Administration of Targeted Immunotherapy. Clinical Cancer Research, 2008, 14, 5512-5518.	7.0	23
78	Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. Breast Cancer Research and Treatment, 2011, 128, 147-154.	2.5	23
79	Autologous cellular immune response to primary and metastatic human melanomas and its regulation by DR antigens expressed on tumor cells. Cancer and Metastasis Reviews, 1985, 4, 7-26.	5.9	22
80	Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas. British Journal of Cancer, 1995, 72, 1397-1399.	6.4	22
81	Caveolin-1 is expressed on multipotent cells of hair follicles and might be involved in their resistance to chemotherapy. British Journal of Dermatology, 2005, 153, 506-513.	1.5	22
82	Allostimulation of patients' lymphocytes generates both T and NK-like cells cytotoxic for autologous melanoma. British Journal of Cancer, 1985, 52, 73-80.	6.4	21
83	Increased Sensitivity to Chemotherapy Induced by CpG-ODN Treatment Is Mediated by microRNA Modulation. PLoS ONE, 2013, 8, e58849.	2.5	21
84	Two Distinct Local Relapse Subtypes in Invasive Breast Cancer: Effect on their Prognostic Impact. Clinical Cancer Research, 2008, 14, 25-31.	7.0	20
85	Antiâ€ŧumor activity of CpGâ€ODN aerosol in mouse lung metastases. International Journal of Cancer, 2013, 133, 383-393.	5.1	20
86	Nerve growth factor directs differentiation of the bipotential cell line GH-3 into the mammotroph phenotype. Endocrinology, 1994, 135, 290-298.	2.8	20
87	Segregation of type 1 cytokine production in human peripheral blood lymphocytes: phenotypic differences between IFN-γ and IL-2-producing cells in the CD8+ T cell subset. European Journal of Immunology, 1998, 28, 3630-3638.	2.9	19
88	Role of hormonal risk factors in HER2-positive breast carcinomas. British Journal of Cancer, 2003, 88, 1032-1034.	6.4	19
89	Expression of activation markers on peripheral-blood lymphocytes following oral administration of bacillus subtilis spores. International Journal of Immunopharmacology, 1993, 15, 87-92.	1.1	18
90	Purification of interleukin-2 antibodies from healthy individuals. Immunology Letters, 1993, 36, 261-266.	2.5	18

#	Article	IF	CITATIONS
91	High efficacy of CpG-ODN, Cetuximab and Cisplatin combination for very advanced ovarian xenograft tumors. Journal of Translational Medicine, 2013, 11, 25.	4.4	18
92	Aerosol Delivery in the Treatment of Lung Cancer. Current Cancer Drug Targets, 2015, 15, 604-612.	1.6	18
93	Natural antibodies to IL-2. Biotherapy (Dordrecht, Netherlands), 1997, 10, 25-28.	0.7	17
94	Toll-like receptor agonists regulate β-defensin 2 release in hair follicle. British Journal of Dermatology, 2007, 156, 1172-1177.	1.5	17
95	CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts. Journal of Translational Medicine, 2016, 14, 25.	4.4	17
96	Toll-like receptor 3 as a new marker to detect high risk early stage Non-Small-Cell Lung Cancer patients. Scientific Reports, 2019, 9, 14288.	3.3	17
97	Proliferation of breast carcinoma during menstrual phases. Lancet, The, 1998, 352, 148-149.	13.7	16
98	Antitumor Efficacy of Trastuzumab in Nude Mice Orthotopically Xenografted With Human Pancreatic Tumor Cells Expressing Low Levels of HER-2/neu. Journal of Immunotherapy, 2008, 31, 537-544.	2.4	16
99	Expression and prognostic significance of the autoimmune regulator gene in breast cancer cells. Cell Cycle, 2016, 15, 3220-3229.	2.6	16
100	Monoclonal antibodies against doxorubicin. International Journal of Cancer, 1988, 42, 798-802.	5.1	15
101	The Differential Response to Interferon \hat{I}^3 by Normal and Transformed Endothelial Cells. Biochemical and Biophysical Research Communications, 1995, 214, 582-588.	2.1	15
102	Local Administration of Caloric Restriction Mimetics to Promote the Immune Control of Lung Metastases. Journal of Immunology Research, 2019, 2019, 1-8.	2.2	15
103	Protection of mice against tumor growth by immunization with an oncogene-encoded growth factor Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 4222-4225.	7.1	14
104	Expansion of Rare CD8+CD28â^'CD11bâ^' T Cells With Impaired Effector Functions in HIV-1–Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 24, 465-474.	2.1	14
105	Virucidal activity of organic acids. Food Chemistry, 1979, 4, 251-258.	8.2	13
106	Skin and Perivascular Toxicity Induced Experimentally by Doxorubicin. Journal of Chemotherapy, 1989, 1, 324-329.	1.5	13
107	Maspin influences response to doxorubicin by changing the tumor microenvironment organization. International Journal of Cancer, 2014, 134, 2789-2797.	5.1	13
108	Inhibition of DNA Repair Mechanisms and Induction of Apoptosis in Triple Negative Breast Cancer Cells Expressing the Human Herpesvirus 6 U94. Cancers, 2019, 11, 1006.	3.7	13

#	Article	IF	CITATIONS
109	Combined targeting of EGFR and HER2 against prostate cancer stem cells. Cancer Biology and Therapy, 2020, 21, 463-475.	3.4	13
110	Human Renal Antigen Defined by a Murine Monoclonal Antibody2. Journal of the National Cancer Institute, 1984, 73, 363-369.	6.3	12
111	T Cells From Individuals in Advanced Stages of HIV-1 Infection Do Not Proliferate but Express Activation Antigens in Response to HIV-1-Specific Antigens. Journal of Acquired Immune Deficiency Syndromes, 1997, 15, 61-69.	0.3	12
112	Inhibition of Human Melanoma Growth in Nude Mice by Autologous, Alloactivated Peripheral Blood Lymphocytes. Tumori, 1984, 70, 35-39.	1.1	11
113	Inhibition of the Biological Activity of Human Interferon-Î ³ by Antipeptide Antibodies. Journal of Interferon Research, 1992, 12, 49-54.	1.2	11
114	Expansion of Rare CD8+CD28â^'CD11bâ^' T Cells With Impaired Effector Functions in HIV-1–Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 24, 465-474.	2.1	11
115	Intestinal Glucose Uptake Protects Liver from Lipopolysaccharide and d-Galactosamine, Acetaminophen, and Alpha-Amanitin in Mice. American Journal of Pathology, 2009, 175, 1066-1076.	3.8	11
116	Sodium glucose cotransporter 1 ligand BLF501 as a novel tool for management of gastrointestinal mucositis. Molecular Cancer, 2014, 13, 23.	19.2	11
117	Correlation between tumor vascularity, vascular endothelial growth factor production by tumor cells, serum vascular endothelial growth factor levels, and serum angiogenic activity in patients with breast carcinoma. Laboratory Investigation, 1999, 79, 897-902.	3.7	11
118	Anti-drug monoclonal antibodies antagonize toxic effect more than anti-tumor activity of doxorubicin. International Journal of Cancer, 1991, 47, 889-892.	5.1	10
119	Most immunoglobulin heavy chain switch mu rearrangements in B-cell chronic lymphocytic leukemia are internal deletions. FEBS Letters, 2002, 518, 119-123.	2.8	10
120	Epithelium–mesenchyme compartment interaction and oncosis on chemotherapy-induced hair damage. Laboratory Investigation, 2004, 84, 1404-1417.	3.7	10
121	Microplate enzyme-linked immunosorbent assay for bovine leukemia virus antibody. Journal of Clinical Microbiology, 1981, 13, 46-48.	3.9	10
122	Aspergillus fumigatus and specific precipitins in dogs with turbinate changes. Veterinary Record, 1981, 108, 143-145.	0.3	10
123	Purification of natural human IFN-Î ³ antibodies. Immunology Letters, 1991, 30, 53-58.	2.5	9
124	Combination of metronomic gimatecan and CpG-oligodeoxynucleotides against an orthotopic pancreatic cancer xenograft. Cancer Biology and Therapy, 2008, 7, 596-601.	3.4	9
125	Dansyl <i>C</i> â€Glucoside as a Novel Agent Against Endotoxic Shock. ChemMedChem, 2010, 5, 1677-1680.	3.2	9
126	A new monoclonal antibody recognizing anthracyclinic molecule. Anticancer Research, 1990, 10, 129-32.	1.1	9

#	Article	IF	CITATIONS
127	INHIBITION OF FIBRONECTIN-ACTIVATED MIGRATION OF MICROVASCULAR ENDOTHELIAL CELLS BY INTERLEUKIN-11 [±] , TUMOUR NECROSIS FACTOR 1 [±] AND INTERFERON 1 ³ . Cytokine, 1999, 11, 134-139.	3.2	8
128	Molecular Phenotype Distinguishes Two Subsets of Gastric Low-Grade Mucosa-Associated Lymphoid Tissue Lymphomas. Laboratory Investigation, 2002, 82, 535-542.	3.7	8
129	Thymic function and immunoglobulin mutation genotype in B-cell chronic lymphocytic leukemia patients. International Journal of Cancer, 2003, 107, 958-961.	5.1	8
130	Innate immunity in breast carcinoma Endocrine-Related Cancer, 2003, 10, 301-308.	3.1	8
131	Apoptosis Induction by Trastuzumab: Possible Role of the Core Biopsy Intervention. Journal of Clinical Oncology, 2005, 23, 7238-7240.	1.6	8
132	Linking survival of HER2-positive breast carcinoma patients with surgical invasiveness. European Journal of Cancer, 2006, 42, 1057-1061.	2.8	8
133	An anti-doxorubicin monoclonal antibody modulates kinetic and dynamic characteristics of the drug. International Journal of Cancer, 1992, 50, 617-620.	5.1	7
134	Intratibial injection of an anti-doxorubicin monoclonal antibody prevents drug-induced myelotoxicity in mice. British Journal of Cancer, 1997, 75, 656-659.	6.4	7
135	Anti-tumor immunity induced by murine melanoma cells transduced with the Mycobacterium tuberculosis gene encoding the 38-kDa antigen. Gene Therapy, 1998, 5, 247-252.	4.5	7
136	Breast carcinoma in young patients. Lancet, The, 2000, 356, 1113.	13.7	7
137	The HER2 World: Better Treatment Selection for Better Outcome. Journal of the National Cancer Institute Monographs, 2011, 2011, 82-85.	2.1	7
138	Influence of fatty acidâ€free diet on mammary tumor development and growth rate in HERâ€2/neu transgenic mice. Journal of Cellular Physiology, 2013, 228, 242-249.	4.1	7
139	Modulation of drug-induced cytotoxicityby a bispecific monoclonal antibodythat recognizes the epidermal growth factor receptorand doxorubicin. Cancer Immunology, Immunotherapy, 1994, 38, 171-177.	4.2	7
140	Tumor-necrosis-factor-induced fibroblast growth factor-1 acts as a survival factor in a transformed endothelial cell line. American Journal of Pathology, 1996, 149, 945-52.	3.8	7
141	Adoptive immunotherapy of cancer with immune and activated lymphocytes: Experimental and clinical studies. Research in Clinic and Laboratory, 1986, 16, 1-20.	0.3	7
142	Cooperative effects of Mycobacterium tuberculosis Ag38 gene transduction and interleukin 12 in vaccination against spontaneous tumor development in proto-neu transgenic mice. Cancer Research, 2000, 60, 3777-81.	0.9	7
143	Immune response to autologous human melanoma: implication of class I and II MHC products. Biochimica Et Biophysica Acta: Reviews on Cancer, 1986, 865, 235-251.	7.4	6
144	Modulation of drug-induced cytotoxicity by a bispecific monoclonal antibody that recognizes the epidermal growth factor receptor and doxorubicin. Cancer Immunology, Immunotherapy, 1994, 38, 171-177.	4.2	6

#	Article	IF	CITATIONS
145	Relevance of Antibody Valency in EGF Receptor Modulation. Scandinavian Journal of Immunology, 1994, 39, 453-458.	2.7	6
146	Lack of Polarized Type 1 or Type 2 Cytokine Profile in Asymptomatic HIVâ€1â€Infected Patients During a Twoâ€Year Bimonthly Followâ€Up. Scandinavian Journal of Immunology, 1998, 47, 146-151.	2.7	6
147	CpG-Oligodeoxynucleotides activate tyrosinase-related protein 2?specific T lymphocytes but do not lead to a protective tumor-specific memory response. Cancer Immunology, Immunotherapy, 2004, 53, 697-704.	4.2	6
148	A Monoclonal Antibody to the NH2-Terminal Region of Human Interferon-Î ³ Inhibits Its Antiproliferative Activity Without Affecting Its Internalization. Journal of Interferon and Cytokine Research, 1995, 15, 197-204.	1.2	5
149	Topical administration of a doxorubicin-specific monoclonal antibody prevents drug-induced mouth apoptosis in mice. British Journal of Cancer, 2001, 85, 1964-1967.	6.4	5
150	Humoral immune response for early diagnosis of breast carcinoma. Annals of Oncology, 2002, 13, 483.	1.2	5
151	Matured human monocyte-derived dendritic cells (MoDCs) induce expansion of CD4+CD25+FOXP3+ T cells lacking regulatory properties. Immunology Letters, 2008, 117, 106-113.	2.5	5
152	Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34+ cells in a xenograft model. Breast Cancer Research and Treatment, 2012, 136, 457-467.	2.5	5
153	Macrophages Impair TLR9 Agonist Antitumor Activity through Interacting with the Anti-PD-1 Antibody Fc Domain. Cancers, 2021, 13, 4081.	3.7	5
154	Expression Profile of Tyrosine Phosphatases in HER2 Breast Cancer Cells and Tumors. Analytical Cellular Pathology, 2010, 32, 361-372.	1.4	5
155	Inhibition of human melanoma growth in nude mice by autologous, alloactivated peripheral blood lymphocytes. Tumori, 1984, 70, 35-9.	1.1	5
156	Serological comparison of Bovid herpesvirus 2 and Herpes simplex virus by reciprocal neutralization kinetic studies. Comparative Immunology, Microbiology and Infectious Diseases, 1980, 3, 509-515.	1.6	4
157	A monoclonal antibody externds the half/life of an anti-HIV oligodeopxynucleotide4 and targets it to CD4+cells. Nucleic Acids Research, 1995, 23, 4603-4607.	14.5	4
158	High level antibody response to retrovirus-associated but not to melanocyte lineage-specific antigens in mice protected against B16 melanoma. , 1999, 83, 107-112.		4
159	HER2 and proliferation of wound-induced breast carcinoma. Lancet, The, 2003, 362, 1503.	13.7	4
160	Modulation of DNA repair genes induced by TLR9 agonists. Oncolmmunology, 2012, 1, 258-259.	4.6	4
161	Prognostic role of tumor size in T1 HER2-positive breast cancers treated with adjuvant trastuzumab. Annals of Oncology, 2014, 25, 1073-1074.	1.2	4
162	Aerosol 1,25-dihydroxyvitamin D3 supplementation: A strategy to boost anti-tumor innate immune activity. PLoS ONE, 2021, 16, e0248789.	2.5	4

#	Article	IF	CITATIONS
163	Influence of Lignans Depletion on Murine Mammary Gland Morphology. Nutrition and Cancer, 2010, 62, 237-242.	2.0	3
164	Control of human melanoma growth in nude mice by autologous allo-activated peripheral blood lymphocytes. International Journal of Cancer, 1986, 38, 923-927.	5.1	2
165	Antigen-specific immunodepression induced by doxorubicin-BSA conjugate in mice. International Journal of Immunopharmacology, 1991, 13, 155-158.	1.1	1
166	Effect of a bifunctional monoclonal antibody directed against a tumor marker and doxorubicin on the growth of epidermoid vulvar carcinoma grafted in athymic mice. Cell Biophysics, 1994, 24-25, 119-126.	0.4	1
167	Re: Italian Randomized Trial Among Women With Hysterectomy: Tamoxifen and Hormone-Dependent Breast Cancer in High-Risk Women. Journal of the National Cancer Institute, 2003, 95, 917-918.	6.3	1
168	Prediction of response to therapy by biomolecular markers: from the research laboratory to the clinic. Annals of Oncology, 2003, 14, 178-179.	1.2	1
169	Antibody Response after Vaccination with Antigen-Pulsed Dendritic Cells. International Journal of Biological Markers, 2004, 19, 213-220.	1.8	1
170	Sodium-dependent glucose transporter-1 as a novel immunological player in the intestinal mucosa Journal of Immunology, 2008, 181, 7428.1-7428.	0.8	1
171	Correction: CCN3 Increases Integrin Expression and Adhesion. Cancer Research, 2008, 68, 2051-2051.	0.9	1
172	PET Prediction of Response to Trastuzumab in ErbB2-Positive Human Xenograft Model. Journal of Nuclear Medicine, 2012, 53, 1654-1655.	5.0	1
173	Increase in the therapeutic effect of doxorubicin induced by monoclonal antibodies raised against this drug. Pharmacological Research, 1992, 26, 141-143.	7.1	Ο
174	Identification of the human switch alpha 2 region from a low-grade malt lymphoma. Mammalian Genome, 2000, 11, 1145-1146.	2.2	0
175	Antibacterial activity and pharmacokinetics in mice of two new derivatives of norfloxacin. Chemioterapia: International Journal of the Mediterranean Society of Chemotherapy, 1987, 6, 176-8.	0.0	0